Understanding Treatment Resistance in BRAF-Mutated Colorectal Cancer
Part of Cancer, Digestive system clinical trials.
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with colorectal cancer that cannot be surgically removed or has spread to other parts of your body (metastatic)
- Your cancer must have a specific genetic mutation called BRAF V600E
- Planning to start treatment with a combination of anti-EGFR antibody and BRAF inhibitor drugs
- At least one tumor that can be safely biopsied (a small tissue sample taken for testing)
- Good enough overall health to tolerate the study (ECOG score 0–2, meaning able to do light activity or self-care)
- Expected to live at least 3 months, age 18 or older, and able to give written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
This trial studies tumor samples from people with metastatic colorectal cancer to understand why treatments stop working. It aims to find new ways to target cancer that has become resistant.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
This trial is researching colorectal cancer that has a specific genetic change called BRAF V600E. It uses advanced testing (multi-omics) to learn more about the cancer and find better ways to treat it.
This real-world study looks at how doctors’ standard treatment works for metastatic colorectal cancer that has a specific BRAF mutation (BRAF V600E). It focuses on patients who are already starting—or will soon start—encorafenib plus cetuximab, using routine care rather than extra trial treatment.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.